Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04141 (
granulocyte-macrophage colony-stimulating factor
)
6,790
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
HB24 is a diverged homeobox gene known to be expressed in hematopoietic progenitor cells. We show here that the inhibition of HB24 expression in CD34+ bone marrow cells via antisense (AS) oligonucleotides impaired the proliferation of these cells in response to interleukin-3 and
granulocyte-macrophage colony-stimulating factor
. The treatment of CD34+ cells with HB24 AS oligonucleotides also reduced the levels of c-fos,
c-myc
, c-myb, cyclin B, and p34cdc2 messenger RNAs compared with cells treated with control oligonucleotides. Conversely, the transient transfection of HB24 into a subpopulation of CD34 cells inhibited their differentiation into mature hematopoietic cell types. In addition, HB24 messenger RNA transcripts were elevated in bone marrow and peripheral blood mononuclear cells isolated from patients with acute myelogenous leukemia compared with normal controls. These data suggest that HB24 is an important transcription factor during hematopoietic progenitor proliferation and that differentiation to specific cell types requires its downregulation. Furthermore, dysregulated expression of HB24 impairs the normal differentiation of hematopoietic progenitors and may contribute to leukemogenesis.
...
PMID:A diverged homeobox gene is involved in the proliferation and lineage commitment of human hematopoietic progenitors and highly expressed in acute myelogenous leukemia. 137 14
Chronically immunosuppressed individuals are susceptible to lymphoreticular tumors. Up to 15% of patients with congenital deficiencies such as ataxia=telangiectasia may develop malignancies, mainly high-grade B cell non=Hodgkin's lymphomas (NHLs). AIDS lymphomas are comprised of NHLs including Burkitt's lymphoma (BL) and primary cerebral lymphomas (PCLs). Almost 3% of all AIDS patients (2824 of 97,258 cases) developed NHL. Epstein-Barr virus (EBV) as a co-factor in AIDS lymphomagenesis has been studied: in 12 cases of 24 AIDS lymphomas EBV by DNA in situ hybridization was found. In an analysis of 6 primary cerebral lymphomas, .5 were positive for EBV DNA by Southern blotting. In Burkitt's lymphoma the characteristic genetic alteration affects the
c-myc
oncogene. In 1/3 of BL p53 mutations were found but none in the 43 NHLs suggesting that p53 mutations and
c-myc
activation act synergistically in the pathogenesis of these tumors. Cytotoxic agents dideoxyinosine, dideoxycytosine, and zidovudine may cause secondary neoplasia. 8 of 55 AIDS patients under zidovudine treatment developed high-grade lymphoma 23.8 months subsequently; recently doses were reduced. PCL was found in 21 of 90 patients. A 5.2 months survival was associated with combined treatment with cyclophosphamide, Oncovin (vincristine), methotrexate, etoposide, and cytosine arabinoside compared with 11.3 months with chemotherapy. Colony-stimulating factors (CSFs) alleviate drug-induced myelotoxicity and zidovudine-induced neutropenia, however, l8 of 11 patients receiving granulocyte-macrophage
CSF
developed hematological toxicity. Interleukine-2 produced by T-helper cells enhancing tumor cells cytotoxicity has been used in AIDS-associated cryptosporidial diarrhea and in 4 patients with AIDS lymphoma with modest response, but its stimulation of the HIV-infected substrate may increase viral proliferation.
...
PMID:AIDS lymphomas. 161 63
Granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) stimulates both the proliferation and functional properties of normal and leukemic myeloid cells via cell surface receptors. The postreceptor mechanisms for these two actions, and the extent to which they represent overlapping biochemical pathways, have not been fully clarified. We have examined the actions of
GM-CSF
on the expression of
c-myc
, an early response oncogene associated with the proliferative stimulus of growth factors.
GM-CSF
reduced the population doubling time of HL-60 leukemia cells from 32 hours to 25 hours, and, at concentrations that were correlated with mitogenicity, induced a rapid twofold increase in the level of c-myc mRNA. Nuclear runoff studies indicated that
GM-CSF
approximately doubled the transcription rate of
c-myc
by reversing the transcription attenuation that occurs at the exon 1-intron 1 junction.
GM-CSF
had no effect on the half-life of
c-myc
messenger RNA. The biochemical basis for the modulation of
c-myc
expression by
GM-CSF
was explored.
GM-CSF
treatment caused intracellular alkalinization of the cells as measured using the fluorescent probe 2', 7-bis (2-carboxyethyl)-5(and-6) carboxyfluorescein (BCECF). The sodium channel blocker amiloride prevented the
GM-CSF
-induced change in pH, but did not affect the stimulation of
c-myc
transcription by
GM-CSF
. Agents that increase cellular cyclic adenosine monophosphate (cAMP) levels (prostaglandin E2 and cholera toxin) blocked the actions of
GM-CSF
on
c-myc
; however, these agents also reduced the basal level of
c-myc
expression.
GM-CSF
caused a rapid (5 minutes) and transient decline in cellular cyclic guanosine monophosphate (cGMP) levels, and a slower (30 minutes) and transient decrease in cellular cAMP levels. These observations are consistent with the hypothesis that the declines in cAMP and cGMP are associated with a stimulation of HL-60 proliferation, while previously reported manipulations that elevate cyclic nucleotides are related to an inhibition of HL-60 proliferation and the potentiation of differentiation.
...
PMID:Regulation of c-myc expression by granulocyte-macrophage colony-stimulating factor in human leukemia cells. 164 47
The human monoblast cell line, U937, was employed to elucidate early events associated with differentiation induced by
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and 1,25-dihydroxy-Vitamin D3 (VD3). Exposure of cells to a combination of
GM-CSF
and VD3 resulted in an up-regulation of c-fos mRNA within 1 h and a marked down-regulation of c-myc mRNA by 24 h and this was associated with a shift of cell population from the S phase to the G0 + G1 phase of the cell cycle by 18%. This was followed by a marked enhancement of monocyte-associated cell surface antigens [OKM1 (CD11b), LeuM3 (CD14), M77.7], as determined by monoclonal antibodies and flow cytometry. Functional characteristics such as nitroblue-tetrazolium reduction, alpha-naphthyl butyrate esterase activity, and phagocytic capability occurred. Cells treated with
GM-CSF
or VD3 alone showed only minor changes. These results demonstrate a potent synergistic effect of
GM-CSF
and VD3 on induction of U937 differentiation. This differentiation was partially blocked by H7, a protein kinase C (PKC) inhibitor. Changes in
c-myc
and c-fos mRNA expressions and a shift in cell cycle were shown to be early events in this process.
...
PMID:Mechanisms of differentiation of U937 leukemic cells induced by GM-CSF and 1,25(OH)2 vitamin D3. 186 27
An AU-rich sequence present within the 3' untranslated region has been shown to mark some short-lived mRNAs for rapid degradation. We demonstrate by label transfer and gel shift experiments that a 32-kDa polypeptide, present in nuclear extracts, specifically interacts with the AU-rich domains present within the 3' untranslated region of human
granulocyte-macrophage colony-stimulating factor
, c-fos, and
c-myc
mRNAs and a similar domain downstream of the poly(A) addition site of the adenovirus IVa2 mRNA. Competition experiments and partial protease analysis indicated that the same polypeptide interacts with all four RNAs. A single AUUUA sequence in a U-rich context was sufficient to signal binding of the 32-kDa polypeptide. Insertion of three copies of this minimal recognition site led to markedly reduced accumulation of beta-globin RNA, while the same insert carrying a series of U-to-G changes had little effect on RNA levels. Steady-state levels of beta-globin-specific nuclear RNA, including incompletely processed RNA, and cytoplasmic mRNA were reduced. Cytoplasmic mRNA containing the AU-rich recognition sites for the 32-kDa polypeptide exhibited a half-life shorter than that of mRNA with a mutated insert. We suggest that binding of the 32-kDa polypeptide may be involved in the regulation of mRNA half-life.
...
PMID:A 32-kilodalton protein binds to AU-rich domains in the 3' untranslated regions of rapidly degraded mRNAs. 190 42
Tumor necrosis factor alpha (TNF-alpha) has been previously shown to modulate the expression of hematopoietic growth factor genes in monocytes and other mesenchymal cells. As acute myeloblastic leukemia (AML) blasts can express and produce hematopoietic growth factors, the influence of TNF-alpha on the accumulation of mRNAs for
c-myc
, interleukin-3 (IL-3),
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
), G-CSF, IL-6 and IL-1 beta was evaluated in fresh blasts from 13 patients with AML. Total cellular RNA was extracted from blast cells cultured for 24 hours with or without TNF-alpha (500 U/ml). The
c-myc
transcript level was decreased by TNF-alpha treatment in 9/13 cases, and increased in only one case. Among the growth factor genes, the
GM-CSF
gene was more often and consistently influenced by TNF-alpha, increased levels of its transcript being observed in 6/13 cases following treatment with the cytokine; in no case was there a reduction of
GM-CSF
mRNA. G-CSF and IL-6 transcripts were more heterogeneously influenced, whereas the IL-3 transcript was never detected in our AML samples. The IL-1 beta message was present in 8/13 untreated and in 13/13 TNF-alpha treated samples. Moreover, in untreated cells,
GM-CSF
, G-CSF and IL-6 expression was always associated with IL-beta expression. These findings indicate that TNF-alpha can modulate the levels of growth factor transcripts in AML blasts, and raise questions about the effects of TNF-alpha on leukemic hematopoiesis, considering that TNF-alpha, IL-1 and
GM-CSF
can synergistically stimulate the growth of AML clonogenic cells.
...
PMID:Tumor necrosis factor alpha modulates the messenger RNA expression of hematopoietic growth factor genes in fresh blast cells from patients with acute myeloblastic leukemia. 196 Oct 22
Previous studies showed that factor-independent, late-passage HL60 acute nonlymphocytic leukemia (ANLL) cells proliferated in response to
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) after treatment with dimethylsulfoxide (DMSO) or other agents inducing cellular differentiation. In the present studies, we examined mechanisms of this response. After treatment with DMSO,
GM-CSF
delayed expression of some HL60 differentiation programs (CD11b expression), but not others (nitro blue tetrazolium dye reduction), and delayed the exit of cells from the cell cycle. In the presence of DMSO,
GM-CSF
but not granulocyte colony-stimulating factor (G-CSF) increased expression of steady-state
c-myc
RNA. DMSO-treated HL60 cells expressing heterologous epidermal growth factor (EGF) receptors also proliferated in response to EGF and showed increased
c-myc
expression. Nuclear transcription studies showed that
GM-CSF
did not alter
c-myc
transcription in DMSO-treated cells, and studies using actinomycin-D showed no increase in steady-state
c-myc
RNA half-life. These studies indicate that
GM-CSF
increases post-deterministic proliferation and alters the phenotype of differentiating HL60 cells, and post-transcriptional alterations in
c-myc
expression may be responsible for some of these changes. Heterologous EGF receptors mediate similar responses, suggesting that treating HL60 cells with DMSO may reveal a common pathway of growth factor gene regulation.
...
PMID:Analysis of granulocyte-macrophage colony-stimulating factor action in differentiating myeloid leukemia cells: treatment with DMSO may reveal a common pathway for growth factor gene regulation. 199 12
The effect of
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) and macrophage colony-stimulating factor (M-CSF) on the expression of c-fos and
c-myc
protooncogenes was studied in rat alveolar macrophages (AM). AM were exposed in vitro to
GM-CSF
(100 U/ml) or M-CSF (1,000 U/ml) for 30-120 min, and c-fos and c-myc mRNA expression was determined by in situ hybridization and Northern blot analysis.
GM-CSF
caused a rapid induction of c-fos mRNA after 30 min and c-myc mRNA after 60 min. Exposure to M-CSF stimulated maximal expression of c-fos mRNA after 60 min and c-myc mRNA after 120 min. Under the same experimental conditions lipopolysaccharide (100 ng/ml) induced a comparable amount of c-fos and c-myc mRNA expression, whereas culture of AM with medium alone did not induce c-fos or
c-myc
expression. Thus
GM-CSF
and M-CSF induce AM in vitro to express the nuclear protooncogenes c-fos and
c-myc
. This effect of colony-stimulating factors on protooncogene expression may be of importance in the local regulation of AM activation and/or proliferation in an inflammatory lung response.
...
PMID:Colony-stimulating factor induction of protooncogene expression in rat alveolar macrophages. 211 33
Rapid turnover of the
c-myc
message mediates both the low basal level of mRNA and the rapid response to changes in transcription. The primary RNA instability determinant (RID sequence) resides in the 3' untranslated region (UTR), within an 80 base region that is rich in A and U residues. In contrast to
granulocyte-macrophage colony-stimulating factor
(
GM-CSF
) mRNA in which the RID sequence has been mapped to a repeating AUUUA sequence, mutation of the only copy of this sequence in the
c-myc
3' UTR has no effect on RNA turnover. Thus the
c-myc
RID sequence appears to be quite different from that of
GM-CSF
, which may account for the differential regulation of half-life exhibited by these mRNAs. c-myc mRNA turnover is also tightly coupled to translation since translational inhibitors stabilize this mRNA. Mutation of the initiating AUG to a termination codon stabilizes
c-myc
RNA, arguing that loading with polysomes (perhaps accompanied by localization on the cytoskeleton) is also required for proper message turnover.
...
PMID:cis-acting determinants of c-myc mRNA stability. 213 48
Murine T helper type 2 clones were stimulated with immobilized anti-CD3 antibody or with recombinant lymphokines to compare the expression of T-cell activation genes induced by these stimuli. Immobilized anti-CD3 antibody, recombinant interleukin 2 (IL-2), and recombinant interleukin 4 (IL-4) all induced proliferation of the T helper type 2 clones 10-5-17 and D10. Proliferation of these clones induced by anti-CD3 antibody was completely inhibited by cyclosporine A, whereas cyclosporine A had little effect on proliferation induced by recombinant IL-2 or recombinant IL-4. Both immobilized anti-CD3 antibody, and recombinant IL-2 induced the expression of the protooncogenes
c-myc
and c-myb. Immobilized anti-CD3 antibody also induced expression of the lymphokine genes IL-4, interleukin 5 (IL-5), and
granulocyte-macrophage colony-stimulating factor
. In contrast, recombinant IL-2 induced IL-5 mRNA expression but did not induce detectable expression of IL-4 or
granulocyte-macrophage colony-stimulating factor
mRNA. Likewise, recombinant IL-4 induced expression of IL-5 but not IL-4 mRNA. Thus, the IL-4 and IL-5 genes appear to be differentially regulated after stimulation with recombinant lymphokines. Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation. Cyclosporine A completely inhibited anti-CD3-induced expression of IL-4 mRNA but not of IL-5 mRNA, and protein-synthesis inhibitors completely inhibited induction of IL-5 mRNA but not of IL-4 mRNA. Together, our data show that T-cell receptor-mediated and lymphokine receptor-mediated signals induce different patterns of lymphokine gene expression and provide strong evidence that the IL-4 and IL-5 genes are differently regulated.
...
PMID:Differential regulation of interleukin 4 and interleukin 5 gene expression: a comparison of T-cell gene induction by anti-CD3 antibody or by exogenous lymphokines. 214 29
1
2
3
4
5
Next >>